Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets

Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets Ahmedabad, 22 December, 2021 Zydus Cadila has received tentative approval from the USFDA to market Pimavanserin Tablets, 10 mg (US RLD: Nuplazid Tablets). Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there ( hallucinations) and false beliefs (delusions). The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally. ***

The release as fetched from its publisher. zyduslife.com ↗